Manhattan Research, LLC Blog Waiting to hit the billion dollar 'Jak'pot with oral small molecule inhibitors in rheumatoid arthritis

Jak inhibitors continue to be the most active area of drug development for RA. At the 2016 EULAR Congress held June 8-11 in London, many presentations focused on important aspects of RA management including the optimization of methotrexate dosing, value of ultrasound-assisted treatment strategies, and tapering of biologics dosages. However, data on novel therapies highlighting [...]The post Waiting to hit the billion dollar 'Jak'pot with oral small molecule inhibitors in rheumatoid arthritis appeared first on DRG.